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Objective: To evaluate anti-Candida and anti-Cryptococcus activities of 15 non-
alkaloidal compounds from Pterogyne nitens Tulasne (Leguminosae), a South Amer-
ican medicinal plant.
Methods: Compounds were submitted to antifungal assays, using microdilution method
described by Clinical and Laboratory Standards Institute document, with minor modiﬁ-
cations. Five species of Candida and two species of Cryptococcus, including clinical
isolates were screened. Antifungal activity was expressed by minimum inhibitory con-
centration (MIC). Amphotericin B and ﬂuconazole were used as standard antifungal drugs.
Results: Among tested compounds, six substances presented fungal growth inhibition
(MIC< 31.2 mg/mL) [three ﬂavone derivatives (1–3), a glycosylated ﬂavonol derivative (5)
and two phenolic acids (10 and 12)]. Sorbifolin (1), exhibited potent antifungal activity,
demonstrating MIC value of 3.90 mg/mL against Candida glabrata ATCC 90030, Cryp-
tococcus gattii 118 and ﬂuconazole-resistant clinical isolate of Cryptococcus neoformans
var. grubii. Pedalin (2) and nitensoside B (3), two glycosylated ﬂavone derivatives, were
active against Cryptococcus neoformans ATCC 90012 (MIC = 7.80 mg/mL).
Conclusions: Flavone derivatives from Pterogyne nitens can serve as prototypes for the
design and development of innovative anti-Candida and anti-Cryptococcus hits.1. Introduction
In the last decades, there has been a signiﬁcant increase in the
incidence and prevalence of opportunistic fungi infections,including candidiasis and cryptococcosis. This increase is related to
the growing number of immunocompromised patients, including
those with AIDS, cancer, transplant recipients and premature neo-
nates [1,2]. Seven Candida species are classiﬁed as having major
clinical relevance, namely, Candida albicans (C. albicans),
Candida tropicalis (C. tropicalis), Candida glabrata (C.
glabrata), Candida parapsilosis (C. parapsilosis), Candida
krusei (C. krusei), Candida stellatoidea and Candida kyfer [3–6].
Candidiasis, the most common opportunistic yeast infection in
the world has been in majority with C. albicans. This yeast is a
causative agent of mucocutaneous and vulvovaginal infections,
among other more invasive infections, such as septicemia,
endocarditis, meningitis and peritonitis [3,4,7]. Cryptococcosis is
an important globally systemic mycosis and the third most. This is an open access article under the CC BY-
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manifestation is cryptococcal meningitis, which has been mainly
caused by Cryptococcus neoformans (C. neoformans) and
Cryptococcus gattii (C. gattii). However, there are reports of
human infections caused by C. albidus and Cryptococcus
laurentii [9].
On the other hand, the inefﬁcacy of conventional antifungal
drugs against resistant strains, as well as their severe side effects,
limited spectrum of action and drug–drug interactions justify the
urgent search for novel antifungal compounds [10]. In this way,
natural products have long been used as prototypes for design of
innovative drugs, which may be useful against infectious diseases,
such as artemisinin, quinine, b-lactams, aminoglycosides, tetra-
cyclines, echinocandins, griseofulvin, etc. [11]. Several metabolites
of diverse structural patterns have proven to be active against
fungi, as well as the screening of plant extracts is a valid strategy
being exploited to discover novel antifungal agents [12,13].
Pterogyne nitens Tulasne (Leguminosae) (P. nitens), popularly
named as “ba´lsamo”, “cocal”, “amendoim-bravo”, “amendoin-
zeiro” and “yvi-raro´” is the sole member of the genus. It is found in
non-protected South America areas, belonging to the list of species
recommended for conservation genetics in Brazil. Also,P. nitens is
admired for the beauty and odor of its ﬂowers, leaves and fruits [14].
Ethnopharmacological studies in Guarani communities revealed
cold aqueous preparations from P. nitens stem barks have been
used for the treatment of helminthic infestations, mainly against
Ascaris lumbricoides [15]. Chemically, P. nitens presented a
variety of compounds, including guanidine alkaloids, ﬂavonoids
(ﬂavones, ﬂavonols, ﬂavan-3-ols and catechins), phenolic acids,
triterpenes and sterols [16–19]. Guanidine alkaloids from P. nitens
have demonstrated a broad spectrum of biological activities,
including cytotoxic, pro-apoptotic, antibacterial and trypanocidal
activity [20–25]. Flavones and ﬂavonols from P. nitens exhibited
myeloperoxidase inhibitory and antioxidant activities [26–29].
In our previous study, we identiﬁed antimicrobial activity of
P. nitens extracts and their four guanidine alkaloids against
C. albicans, C. krusei, C. parapsilosis and C. neoformans [30].
Our goal with present work was to evaluate anti-Candida and
anti-Cryptococcus activities of 15 non-alkaloidal compounds
against ﬁve Candida species and two Cryptococcus species.
2. Materials and methods
2.1. Non-alkaloidal compounds from P. nitens
Flavonoids (ﬂavone, ﬂavonol and catechin derivatives) (1–8)
and phenolic acids (9–13) were isolated and identiﬁed, using
chemical procedures reported previously (Figure 1). Flavone de-
rivatives, sorbifolin (1), pedalin (2) and nitensoside B (3), were
isolated from leaves [26]. Flavonol derivatives, quercetin (4),
isoquercitrin (5), quercetin 3-O-sophoroside (6) and rutin (7)
were obtained from fruits and ﬂowers [27,31]. Ourateacatechin (8)
and the phenolic acids (9–13), such as caffeic acid (9), ferulic
acid (10), sinapic acid (11), chlorogenic acid (12) and gallic acid
(13) were isolated from ﬂowers [18].
Triterpene acids (14) and (15) were puriﬁed from P. nitens
leaves for the ﬁrst time. Leaves of P. nitens were collected from
Institute of Biosciences, Letters and Exact Sciences, São Paulo
State University, São Jose do Rio Preto, Sao Paulo, Brazil
(2047002.400 S, 4921036.000 W) in July 2014 and a voucher
specimen (10291) was deposited in the Herbarium of Ilha Sol-
teira (HISA) of Faculty of Engineering, Ilha Solteira, São Paulo,Brazil. Shade-dried leaves (600 g) were ground and extracted
with hexane (1.8 L × 3, at room temperature). Dry hexane
extract (10 g) was subjected to puriﬁcation by successive
chromatography columns over silica gel, eluted with mixtures of
hexane and ethyl acetate, as well as furnishing betulinic acid (14
and 20 mg) and oleanonic acid (15 and 14 mg) (Figure 1).
Structures of compound 14 and 15 were identiﬁed according to
literature data, including 13C nuclear magnetic resonance spec-
trum analysis [32].
2.2. Microorganisms
Six ATCC biological standards were used in our preliminary
experiments, including C. albicans ATCC 90028, C. krusei
ATCC 6258, C. parapsilosis ATCC 22019, C. glabrata ATCC
90030, C. tropicalis ATCC 750 and Cryptococcus neoformans
var. grubii (C. neoformans var. grubii) ATCC 90012. Two clin-
ical isolates of C. neoformans var. grubii, ﬂuconazole-resistant
[C. neoformans clinical resistant (CnR)] and ﬂuconazole-
susceptible [C. neoformans clinical susceptible (CnS)], were
obtained from AIDS patient with recurrent cryptococcosis [33].
Fluconazole-resistant isolate of C. gattii (118) was obtained
from psittacine birds [34]. All yeasts were obtained from the
collection of Laboratory of Clinical Mycology, Department of
Clinical Analyses, School of Pharmaceutical Sciences,
Universidade Estadual Paulista (UNESP), Araraquara, São
Paulo, Brazil.
2.3. Minimum inhibitory concentration (MIC)
Dissolution of compounds was performed with dime-
thylsulfoxide on 96-well plates and their concentration ranged
from 250.00 to 0.48 mg/mL. Anti-Candida and anti-Crypto-
coccus activity experiments were carried out using reference
broth microdilution method, as outlined in M27-A3 document
produced by Clinical and Laboratory Standards Institute [35],
with minor modiﬁcations [36]. Amphotericin B and ﬂuconazole
(FCZ) were used as standard antifungal drugs. MIC values
were determined as the lowest concentration of test samples
which showed complete fungal growth inhibition. Some 96-
well plates were analyzed visually and spectrophotometrically.
All tests were performed in triplicate and in the three indepen-
dent experiments.
3. Results
MIC values for all yeasts were given in Table 1. Out of 15
non-alkaloidal compounds (1–15), six substances presented
fungal growth inhibition (MIC  31.20 mg/mL) including three
ﬂavone derivatives (1–3), a glycosylated ﬂavonol derivative (5)
and two phenolic acids (10 and 12).
Compound 1 demonstrated potent antifungal activity against
both human opportunistic fungi, with MIC values ranging from
3.90 to 31.20 mg/mL. In anti-Candida assays, the most potent
effect of compound 1 was against C. glabrata (MIC = 3.90 mg/
mL), followed by C. krusei and C. parapsilosis (MIC = 7.80 mg/
mL). The lowest potency of compound 1 was against
C. albicans and C. tropicalis (MIC = 31.20 mg/mL). In the anti-
Cryptococcus assays, compound 1 was active against three
strains of C. neoformans var. grubii (MIC values of 3.90 and
7.80 mg/mL), including ﬂuconazole-resistant clinical isolate
(CnR). For CnR strain, compound 1 exhibited a MIC value of
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Figure 1. Structure of non-alkaloidal compounds from P. nitens.
1: Sorbifolin; 2: Pedalin; 3: Nitensoside B; 4: Quercetin; 5: Isoquercitrin; 6: Quercetin 3-O-sophoroside; 7: Rutin; 8: Ourateacatechin; 9: Caffeic acid; 10:
Ferulic acid; 11: Sinapic acid; 12: Chlorogenic acid; 13: Gallic acid; 14: Betulinic acid; 15: Oleanonic acid.
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has been administered as gold standard for cryptococcosis
treatment [37]. Compound 1 was active against C. gattii (118),
displaying a MIC value of 3.90 mg/mL, four times less potent
than amphotericin B. For C. neoformans var. grubii ATCC
90012 and CnS strains, compound 1 (MIC = 7.80 mg/mL) was
two times less potent than FCZ (MIC = 4.00 mg/mL).
Compounds 2 and 3, two glycosylated ﬂavone derivatives, were
active against C. neoformans var. grubii (ATCC 90012), with MIC
values of 7.80 mg/mL, two times less potent than FCZ
(MIC = 4.00 mg/mL). On the other hand, compounds 2 and 3
exhibited weak fungitoxicity against Candida species (MIC >Table 1
MIC values of non-alkaloidal compounds (1–15) from P. nitens. mg/mL.
Compounds C. albicans
ATCC 90028
C. krusei
ATCC 6258
C. parapsilosis
ATCC 22019
C. gl
ATCC
1 31.20 7.80 7.80
2 250.00 31.20 125.00
3 250.00 62.50 125.00
4  250.00  250.00  250.00  2
5 250.00 62.50 250.00
6 250.00 250.00 250.00
7  250.00  250.00  250.00  2
8  250.00  250.00  250.00  2
9  250.00  250.00  250.00  2
10  250.00 125.00  250.00  2
11  250.00  250.00  250.00  2
12  250.00  250.00  250.00  2
13  250.00  250.00  250.00  2
14  250.00  250.00  250.00  2
15  250.00  250.00  250.00  2
FCZa 8.00 – 16.00
Amphotericin Ba – 2.00 –
a: Standard antifungal drugs.62.50 mg/mL), except compound 2 which was moderately active
against C. krusei (MIC = 31.20 mg/mL).
Interestingly, ﬂavonols, compound 4 and its glycosylated
derivatives (5–7) were signiﬁcantly less fungitoxic than ﬂavone
derivatives (1–3). Among ﬂavonol derivatives, compound 5
demonstrated potent anti-Cryptococcus activity against ATCC
strain, displaying a MIC value of 15.60 mg/mL, four times less
potent than FCZ (MIC = 4.00 mg/mL). For this strain, com-
pounds 4, 6 and 7 were weakly active, exhibiting MIC values of
125.00, 62.50 and 125.00 mg/mL, respectively. The comparison
of MIC values for compounds 4–7 indicated number of sugar
units inﬂuenced anti-Cryptococcus effect. Thus, order ofabrata
90030
C. tropicalis
ATCC 750
C. neoformans
ATCC 90012
CnS CnR C. gattii (118)
3.90 31.20 7.80 7.80 3.90 3.90
– – 7.80 – – –
– – 7.80 – – –
50.00  250.00 125.00 – – 125.00
– – 15.60 – – –
– – 62.50 – – –
50.00  250.00 125.00 – – 125.00
50.00  250.00 125.00 – – 125.00
50.00  250.00 125.00 – – 125.00
50.00  250.00 31.20 – – 31.20
50.00  250.00 125.00 – – 125.00
50.00  250.00 31.20 – – 31.20
50.00  250.00 125.00 – – 125.00
50.00  250.00 125.00 – – 125.00
50.00  250.00 125.00 – – 125.00
– 8.00 4.00 4.00 – –
0.50 – – – 1.00 1.00
Caroline Sprengel Lima et al./Asian Pac J Trop Biomed 2016; 6(10): 841–845844antifungal potency was monoglycosylated (5) > diglycosylated
(6 and 7) > free aglycone (4).
Among phenolic acids (9–13), compounds 10 and 12
exhibited moderate anti-Cryptococcus activity (MIC = 31.20 mg/
mL) against C. neoformans (ATCC 90012) and C. gattii (118).
Compounds 8, 14 and 15 were not active against both yeasts
species (MIC  125 mg/mL).
4. Discussion
MIC values of compounds 1–3 corroborate antifungal po-
tential of ﬂavone derivatives, which have shown fungitoxicity
against a broad spectrum of fungi species, including yeasts
(Saccharomyces cerevisiae), halohyphomycetes (Aspergillus)
and dermatophytes (Trichophyton and Epidermophyton) [38–40].
Nevertheless, our results to compound 1 were signiﬁcantly
opposite to those described by Taleb-Contini et al., who re-
ported absent growth inhibition until 500 mg/mL against
C. albicans ATCC 1023 and C. tropicalis (clinical isolate from
oral cavity), by using well diffusion assay [41]. This difference
may be related to strain types, susceptibility tests and/or purity
grade of compounds.
Reviewof literature data on anti-Candida activity of compounds
4, 10 and 13 is conﬂicting. A commercial sample of compound 4
presented higher anti-C. albicans activity (MIC = 8 mg/mL) than
isolate samples from Buddleja salviifolia (MIC = 125 mg/mL) and
Halimodendron halodendron (MIC = 250 mg/mL) [42–44]. Similar
behavior was observed for commercial gallic acid (MIC = 8 mg/
mL) in comparison to the one obtained from Lythrum salicaria
(MIC = 2500 mg/mL), Paeonia rockii (MIC = 30 mg/mL) and
Pelargonium reniforme subsp. reniforme (MIC = 500 mg/mL)
[42,45–47]. Also, commercial sample of compound 10
(MIC = 20 mg/mL) was quite different to sample obtained from
Halimodendron halodendron (MIC = 200 mg/mL) [44,48]. Our
anti-C. albicans MIC value data were more similar to plant
isolates than commercial samples.
Commercial samples of compounds 9 and 12 displayed MIC
values of 8 and 16 mg/mL againstC. albicans andC. parapsilosis,
respectively [42]. In contrast, our MIC value data for compounds 9
and 12 against both yeasts were equal or superior to 250 mg/mL.
Compound 7 from P. nitens was not able to exhibit anti-
C. albicans activity (MIC  250 mg/mL), on the other hand,
rutin commercial sample displayed the potent effect
(MIC = 40 mg/mL) [48]. Martins et al. suggested that these
differences could be probably assigned to purity grade of tested
compounds [49]. Additionally, we inferred this difference may
be correlated to strain types.
In summary, 15 non-alkaloidal compounds from P. nitens
were evaluated against Candida and Cryptococcus species. Of
these, compound 1 may be considered suitable template for
design of innovative hits for the treatment of opportunistic yeast
infections, including candidiasis and cryptococcosis.
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